[Immunosuppressive therapy of XXXX . Long term follow-up evaluation (author's transl)].

@entity1 @entity231 @entity5805 @entity1939 @entity1503 @entity2403
18 @entity1 suffering from @entity2403 were treated with @entity5805 . In addition 6 @entity1 who were threatened by acute and permanent @entity1939 received antilymphocyte globulines. The follow-up varies from 1 to 12 years with an average of 4,5 years. Recovery from ocular inflammation was total in 14 @entity1 , and partial in 4 @entity1 . 6 eyes underwent an uneventful @entity231 extraction. None of the 8 one-eyed @entity1 became blind. The mean improvement of visual acuity at the end of the follow-up period was 0,4. However recurrences occurred in 3 @entity1 when the treatment was stopped. In this series blood cell tolerance was the major problems encountered. The results achieved in this series lead to confirm that @entity5805 and A.L.G. have dramatically improved the ocular prognosis of @entity2403 . However @entity5805 must not be considered to be the ultimate answer to the treatment of @entity2403 since recurrences occur when the treatment has been stopped. In addition to this, long term treatments with @entity5805 involve a high risk of severe @entity1503 .
